Leukemia Clinical Trials in Florida

Showing 541-560 of 882 trials

P3 (Prepared, Protected, emPowered)

NCT03320512

P3 (Prepared, Protected, emPowered) is an interactive smartphone app for HIV-uninfected YMSM and YTW that utilizes social networking and game-based mechanics as well as a comprehensive understanding of what constitutes "best practices" in app development to improve PrEP adherence and persistence in PrEP care.

Sexually Transmitted DiseasesSafe SexAdherence, Medication

University of North Carolina, Chapel Hill246 participantsStarted May 2019

Tampa, Florida, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +6 more locations

TERMINATEDPhase 149 miles

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

NCT04022876

This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line treatment with topotecan. (Part 1 has completed enrollment). Part 2 NSCLC is a randomized, double-blind, placebo-controlled, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated advanced NSCLC of adenocarcinoma histology receiving 1st-line treatment with carboplatin plus pemetrexed with or without immunotherapy.

Non Small Cell Lung CancerSmall-cell Lung Cancer

Aileron Therapeutics, Inc.35 participantsStarted Sep 2019

Kingman, Arizona, United States • Miami, Florida, United States • Tamarac, Florida, United States +25 more locations

PreviousPage 28 of 45Next

P3 (Prepared, Protected, emPowered)

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Leukemia Trials in Other Cities

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Predictive Assay for Decision Making in Adjuvant Therapy

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

A Study of PLX2853 in Advanced Malignancies.

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Other Conditions in Florida